The E-selectin inhibitor Uproleselan (GMI-1271), developed by GlycoMimetics, has shown promise for treating acute myeloid leukaemia (AML) in combination with chemotherapy (NCT02306291) [175,236,237], with phase III trial results expected in 2023 (NCT03616470), and may also re-sensitise multiple myeloma to therapy [235]. Here, SELE is linked to acute myeloid leukemia.